BioCentury | Apr 7, 2017
Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
BC Week In Review | Feb 24, 2017
Clinical News

Sapacitabine: Additional Ph III SEAMLESS data

The open-label, international Phase III SEAMLESS trial in 491 newly diagnosed AML patients ages ≥70 years who were not candidates for, or who refused, intensive induction chemotherapy showed that alternating cycles of sapacitabine and Dacogen...
BC Extra | Feb 23, 2017
Clinical News

Cyclacel's sapacitabine fails in Phase III AML trial

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) lost $1.36 (25%) to $4.05 on Thursday after its sapacitabine ( CYC682 ) missed the primary endpoint in the pivotal Phase III SEAMLESS trial to treat newly diagnosed acute myelogenous leukemia in elderly...
BioCentury | Sep 7, 2015
Strategy

Back to School: Changing the subject

No longer content with a walk-on role as research subjects, and empowered by access to more information and the necessity of shouldering a bigger share of the healthcare bill, patients are demanding a speaking role...
BioCentury | Jul 13, 2015
Finance

Big news

The performance of big cap biotechs has lagged that of companies one tier down, but the second half includes a host of milestones that could put the bellwethers on a steeper upward trajectory. Buysiders largely...
BioCentury | Jan 5, 2015
Finance

4Q14 Stock Wrap-up: Grow early, grow often

Biotech stocks rose in 4Q14, with only the microcaps segment, with valuations under $200 million, finishing down. The rally followed two quarters in which only the large cap segment, with valuations over $5 billion, were...
BC Week In Review | Dec 22, 2014
Clinical News

Sapacitabine: Interim Phase III data

Cyclacel said a planned interim analysis for futility by an independent DSMB after 247 deaths occurred in the open-label, international Phase III SEAMLESS trial showed that 20 mg/m 2 IV decitabine for 5 consecutive days...
BioCentury | Dec 22, 2014
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/19 cls BioDelivery Sciences International Inc. (NASDAQ:BDSI) Roth Capital Partners Scott Henry Upgrade Buy (from neutral) 0% $13.82 Henry upgraded...
BC Extra | Dec 17, 2014
Clinical News

Cyclacel plummets on futility analysis

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) dropped $2.15 (76%) to $0.68 after oral sapacitabine ( CYC682 ) failed a futility analysis of survival in a Phase III trial to treat acute myelogenous leukemia (AML). The Data and Safety Monitoring...
BC Week In Review | Nov 3, 2014
Clinical News

Sapacitabine: Phase III ongoing

Cyclacel said an independent DSMB recommended continuation of the open-label, international Phase III SEAMLESS trial of oral sapacitabine based on available data from 317 patients with >=60 days of follow-up showing no safety or efficacy...
Items per page:
1 - 10 of 84